Actuele ontwikkelingen in het familierecht : verslag van het 13e UCERF-symposium

Elk jaar organiseert het Utrecht Centre for European Research into Family Law (UCERF) in het voorjaar een symposium met als terugkerend thema ‘Actuele ontwikkelingen in het familierecht’. UCERF is de onderzoeksgroep van de Universiteit Utrecht waar onderzoek wordt gedaan naar families en recht (www.uu.nl/ucerf). Tijdens het symposium presenteren onderzoekers van UCERF, andere wetenschappers en professionals uit de praktijk hun werk. Op 18 april 2019 vond alweer de 13e editie van dit symposium plaats met een divers en boeiend programma. Zo’n 170 juridische professionals verzamelden zich op deze zonnige middag in de aula van het Academiegebouw in Utrecht. Dit verslag geeft een korte impressie van de presentaties en de discussies die deze dag hebben plaatsgevonden

Actuele ontwikkelingen in het familierecht : verslag van het 13e UCERF-symposium

Elk jaar organiseert het Utrecht Centre for European Research into Family Law (UCERF) in het voorjaar een symposium met als terugkerend thema ‘Actuele ontwikkelingen in het familierecht’. UCERF is de onderzoeksgroep van de Universiteit Utrecht waar onderzoek wordt gedaan naar families en recht (www.uu.nl/ucerf). Tijdens het symposium presenteren onderzoekers van UCERF, andere wetenschappers en professionals uit de praktijk hun werk. Op 18 april 2019 vond alweer de 13e editie van dit symposium plaats met een divers en boeiend programma. Zo’n 170 juridische professionals verzamelden zich op deze zonnige middag in de aula van het Academiegebouw in Utrecht. Dit verslag geeft een korte impressie van de presentaties en de discussies die deze dag hebben plaatsgevonden

Plasma GDF-15 concentration is not elevated in open-angle glaucoma

Aim Recently, the level of growth differentiation factor 15 (GDF-15) in blood, was proposed as biomarker to detect mitochondrial dysfunction. In the current study, we evaluate this biomarker in open-angle glaucoma (OAG), as there is increasing evidence that mitochondrial dysfunction plays a role in the pathophysiology of this disease. Methods Plasma GDF-15 concentrations were measured with ELISA in 200 OAG patients and 61 age-matched controls (cataract without glaucoma). The OAG patient group consisted of high tension glaucoma (HTG; n = 162) and normal tension glaucoma (NTG; n = 38). Groups were compared using the Kruskal-Wallis nonparametric test with Dunn’s multiple comparison post-hoc correction. GDF-15 concentration was corrected for confounders identified with forward linear regression models. Results Before correcting for confounders, median plasma GDF-15 levels was significantly lower in the combined OAG group (p = 0.04), but not when analysing HTG and NTG patients separately. Forward linear regression analysis showed that age, gender, smoking and systemic hypertension were significant confounders affecting GDF-15 levels. After correction for these confounders, GDF-15 levels in OAG patients were no longer significantly different from controls. Subgroup analysis of the glaucoma patients did not show a correlation between disease severity and plasma GDF-15, but did reveal that for NTG patients, intake of dietary supplements, which potentially improve mitochondrial function, correlated with lower plasma GDF-15. Conclusion The present study suggests that plasma GDF-15 is not suited as biomarker of mitochondrial dysfunction in OAG patients

Nail Involvement as a Predictor of Disease Severity in Paediatric Psoriasis: Follow-up Data from the Dutch ChildCAPTURE Registry

Contains fulltext : 201227.pdf (publisher's version ) (Open Access

Commotio cordis

BACKGROUND AND STUDY AIMS: The most frequently cited prevalence for serrated polyposis syndrome (SPS) is 1 in every 3000 people screened, but this value is debated. Additionally, changes in 2010 in the World Health Organization (WHO) diagnostic criteria for SPS might affect reported prevalence. An updated estimate of SPS prevalence is necessary to predict the number of cases in screening programs. PATIENTS AND METHODS: A systematic literature search was conducted in the PubMed, EMBASE, and Web of Science databases up to February 2014. Studies reporting the prevalence of SPS, as defined by WHO criteria, in screening populations were selected. Results : Six studies reported prevalence of SPS in screening populations, varying from 0 to 0.66 %. The highest prevalences (0.34 % and 0.66 %) were seen in studies from screening programs with patients pre-selected by fecal blood test. Primary colonoscopy-based screening programs, that have the lowest risk of bias, reported SPS prevalences ranging from 0 to 0.09 %. Across studies, 56 patients were diagnosed with SPS of whom 3 presented with synchronous colorectal cancer at index endoscopy. CONCLUSION: The true prevalence of SPS is unclear because of the risk of bias across studies, but is likely to be below 0.09 % as derived from primary colonoscopy screening programs. The prevalence in pre-selected screening populations after positive fecal testing is higher, with reported values of 0.34 % and 0.66 %. Large and high quality primary colonoscopy screening studies, reporting SPS prevalence in adequately described populations, are necessary for better estimation of the true prevalence of SPS in average-risk patients